Dupilumab Decreases Concomitant Therapy use in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD

Main Article Content

Raj Chovatiya
Jingdong Chao
Chien-Chia Chuang
Min Yang
Brad Shumel
Bruno Martins
Gaelle Bégo-Le-Bagousse
Debra Sierka
Dimittri Delevry
a:1:{s:5:"en_US";s:30:"Regeneron Pharmaceuticals Inc.";}

Keywords

atopic dermatitis, concomitant therapy, dupilumab

References

1. Dupixent® (dupilumab). Highlights of prescribing information. https://www.regeneron.com/downloads/dupixent_fpi.pdf. Accessed August 8, 2023.

2. Dupixent® (dupilumab). Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product information_en.pdf. Accessed August 8, 2023.

3. Simpson EL, et al. N Eng J Med 2016;375(24):2335-2348.

4. Simpson EL. Dermatol Ther (Heidelb) 2017;7(2):243-248.

5. Deleuran M, et al. J Am Acad Dermatol 2020;82(2):377-388.

6. Simpson EL, et al. JAMA Dermatol 2020;156(1):44-56.

7. Cork MJ, et al. Br J Dermatol 2020;182(1):85-96.

8. Paller AS, et al. J Am Acad Dermatol 2020;83(5):1282-1293.

9. Cork MJ, et al. Br J Dermatol 2021;184(5):857-870.

10. Paller AS, et al. Lancet 2022;400(10356):908-919.

11. Blauvelt A, et al. Am J Clin Dermatol 2022;23(3):365-383.

12. Strober B, et al. JAMA Dermatol 2022;158(2):142-150.

Article Sidebar

PDF
Published
Jan 16, 2024
DOI https://doi.org/10.25251/skin.8.supp.326

Article Details

How to Cite
Chovatiya, R., Chao, J., Chuang, C.-C., Yang, M., Shumel, B., Martins, B., Bégo-Le-Bagousse, G., Sierka, D., & Delevry, D. (2024). Dupilumab Decreases Concomitant Therapy use in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD. SKIN The Journal of Cutaneous Medicine, 8(1), s326. https://doi.org/10.25251/skin.8.supp.326
Issue
Vol. 8 No. 1 (2024): January 2024 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>